Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Parenteral Nutrition Market Heading Into 2029?

The market for personalized cancer vaccines has seen robust growth in recent years. The market is projected to expand from $242.29 billion in 2024 to $256.65 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The historical growth in this market segment can be linked to improved genomic research, the creation of targeted therapies, enhanced knowledge of tumor immunology, advancements in vaccine technology, and an increase in clinical trial data showcasing effectiveness.

The market size of personalized cancer vaccines is predicted to experience robust expansion in the coming years, increasing to a substantial “$329.04 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%.” Contributing factors to this expected surge include advancements in the field of precision medicine, heightened funds designated for cancer research, an upswing in cancer prevalence, enhancements in genetic sequencing techniques, and an increased emphasis on personalized healthcare. Future trends anticipated during this period are the incorporation of artificial intelligence in vaccine development, advancements in multi-antigen and neoantigen-based vaccines, growing utilization of liquid biopsies for tumor tracking, wider implementation of combination therapies, and a sharper focus on individualized treatment plans.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp

Which Factors Are Pushing The Parenteral Nutrition Market Forward?

The escalating incidences of malnutrition worldwide are propelling the expansion of the parenteral nutrition market. Malnutrition implies a deficiency, excess, or imbalance in the consumption of energy or nutrients by an individual. An increase in premature births leading to immune dysfunction and insufficient nutrition has stirred up the need for parenteral nutrition among babies and children. For instance, the United Nations International Children’s Emergency Fund, a US-based entity, stated in May 2023 that undernutrition is responsible for about half of all fatalities in children under the age of 5. Undernutrition escalates the susceptibility of children to common infections, heightens their severity, and prolongs recovery. Therefore, the surging incidences of malnutrition worldwide are anticipated to heighten the demand for parenteral nutrition during the forecast period.

The personalized cancer vaccines market covered in this report is segmented –

1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma

3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action

4) By Route Of Administration: Injectables, Other Routes Of Administration

5) By End Use: Hospitals, Clinic, Other End Users

Subsegments:

1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines

2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines

What Future Market Trends Are Projected For The Parenteral Nutrition Industry?

Key players in the personalized cancer vaccine market are concentrating their efforts on creating innovative therapeutic solutions, like personalized immunotherapy, ensuring a more accurate approach to treating distinctive cancer mutations. Personalized immunotherapy treatments are tailored to make use of individual patient’s genetic composition and tumor attributes to augment the immune system’s fight against cancer. To illustrate, in August 2024, UCLA Health, a healthcare provider based in the United States, initiated an unprecedented clinical trial to appraise the safety and efficacy of a cancer vaccine. The novel vaccine, pioneered at UCLA, utilizes a personalized immunotherapy technique targeting the H3 G34 mutation typically found in diffuse hemispheric gliomas, a notably aggressive brain tumor commonly seen in young adults and teenagers. This strategy uniquely employs dendritic cells to spur the immune system into action against the distinctive RNA disruptions caused by this mutation. This approach, having demonstrated potential in other cancer treatments, aspires to better the prognosis for patients who ordinarily have very few treatment alternatives and a shorter lifespan.

Which Organizations Are Driving Progress In The Parenteral Nutrition Industry?

Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh

https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Parenteral Nutrition Industry?

North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19136&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model